Table 1.
Relationship between PARPBP expression and clinicopathologic factors of breast cancer patients.
| Variables | n = 137 | PARPBP |
p value | |||
|---|---|---|---|---|---|---|
| High | No. (%) | Low | No. (%) | |||
| Age (years) | 1 | |||||
| <50 | 75 | 46 | 33.58% | 29 | 21.17% | |
| ⩾50 | 62 | 38 | 27.74% | 24 | 17.52% | |
| Menopause | 0.857 | |||||
| Yes | 52 | 31 | 22.63% | 21 | 15.33% | |
| No | 85 | 53 | 38.69% | 32 | 23.36% | |
| Tumor status (T) | <0.001* | |||||
| T1 | 35 | 11 | 8.03% | 24 | 17.52% | |
| T2 + T3 + T4 | 102 | 73 | 53.28% | 29 | 21.17% | |
| Lymph node status (N) | <0.001* | |||||
| N0 | 53 | 18 | 13.14% | 35 | 25.55% | |
| N1 | 37 | 22 | 16.06% | 15 | 10.95% | |
| N2 | 22 | 20 | 14.60% | 2 | 1.46% | |
| N3 | 25 | 24 | 17.52% | 1 | 0.73% | |
| Histological grade | 0.295 | |||||
| G1 + G2 | 106 | 62 | 45.26% | 44 | 32.12% | |
| G3 | 31 | 22 | 16.06% | 9 | 6.57% | |
| TNM stage | <0.001* | |||||
| I–II | 87 | 38 | 27.74% | 49 | 35.77% | |
| III–IV | 50 | 46 | 33.58% | 4 | 2.92% | |
| Subtype | 0.353 | |||||
| HR+/HER2+ | 18 | 9 | 6.57% | 9 | 6.57% | |
| HR+/HER2− | 72 | 42 | 30.66% | 30 | 21.90% | |
| HR−/HER2+ | 24 | 18 | 13.14% | 6 | 4.38% | |
| TNBC | 23 | 15 | 10.95% | 8 | 5.84% | |
*
Significant at p < 0.001.
HER2, human epidermal growth factor receptor 2; HR, hormone receptor; PARPBP, PARP1 binding protein; TNBC, triple negative breast cancer; TNM, tumor, node, metastasis.